Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Owusu-Agyei 2006 GHA (Continued)<br />
Free of selective reporting? Yes All WHO outcomes reported. Biochemical<br />
monitoring is stated although this outcome<br />
is not reported<br />
Free of other bias? Yes No other sources of bias identified<br />
Ratcliff 2005 IDN<br />
Methods Trial design: An open-label randomized controlled trial<br />
Follow up: A symptom questionnaire, physical examination, malaria film and<br />
haemoglobin measurement daily until fever and parasites cleared then weekly to day 42<br />
Adverse event monitoring: A symptom questionnaire at each visit<br />
Participants Number: 774 randomized<br />
Inclusion criteria: Weight >10 kg, fever or a history of fever in the preceding 48 hours,<br />
slide confirmed malaria (P. falciparum, P. vivax or mixed infections)<br />
Exclusion criteria: Pregnancy or lactation, danger signs or signs of severity, parasitaemia<br />
> 4%, concomitant disease requiring hospital admission<br />
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose <strong>combination</strong>, 40 mg/320 mg tablets<br />
(Artekin: Holleykin)<br />
• Total dose: DHA 6.75 mg/kg + P 54 mg/kg in 3 divided doses, given once daily<br />
<strong>for</strong> 3 days<br />
2. Artemether-lumefantrine, fixed dose <strong>combination</strong>, 20 mg/120 mg tablets (Coartem:<br />
Novartis)<br />
• 10 to 15 kg 1 tablet twice daily <strong>for</strong> 3 days<br />
• 15 to 25 kg 2 tablets twice daily <strong>for</strong> 3 days<br />
• 25 to 35 kg 3 tablets twice daily <strong>for</strong> 3 days<br />
• > 35 kg 4 tablets twice daily <strong>for</strong> 3 days<br />
Only the first dose of each day was supervized. All participants advised to take each dose<br />
with a biscuit or milk.<br />
Outcomes 1. Parasitological failure at days 42 and 28, PCR adjusted and unadjusted<br />
2. P. vivax during follow up<br />
3. Gametocyte carriage after treatment<br />
4. Anaemia during follow up<br />
5. Adverse events<br />
Not included in the review:<br />
1. Fever clearance<br />
2. Parasite clearance<br />
Notes Country: Indonesia<br />
Setting: Rural outpatient clinics<br />
Transmission: Unstable<br />
Resistance: Multiple-drug resistance<br />
Dates: Jul 2004 to Jun 2005<br />
Funding: Wellcome Trust UK and National Health and Medical Research Council Australia<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
85